Dyno unveils next-gen AI-designed gene delivery capsids targeting brain & muscle

This positions its platform as a rapidly evolving engine for next-generation genetic medicine

MilliporeSigma lands exclusive 5-year deal to test Genetix Biotherapeutics gene therapies

The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy

Eli Lilly unveils $4.5 bn Indiana expansion

The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies

Regeneron and TriNetX forge $200M partnership to supercharge drug discovery and digital health

TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners

Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026

The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations

BNB Plus’ Biopharma subsidiary LineaRx lands major LineaDNA orders

The announcement follows a record-setting $1.2 million accelerated LineaDNA order

Lilly to acquire Orna Therapeutics in deal valued at up to $2.4 billion

The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles

Avista Therapeutics unveils AI-powered expansion of gene therapy platform

The company is rolling out ARTEMIS, a next-generation AI platform for capsid design

Lilly moves forward with $3.56-per-share acquisition of Adverum

Novartis scores FDA nod for game-changing SMA treatment

Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA